NASDAQ:TNDM - Tandem Diabetes Care Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $51.50 +2.22 (+4.50 %) (As of 02/19/2019 04:46 AM ET)Previous Close$49.28Today's Range$50.07 - $52.029952-Week Range$2.39 - $52.55Volume2.24 million shsAverage Volume1.55 million shsMarket Capitalization$2.95 billionP/E Ratio-4.00Dividend YieldN/ABeta0.49 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; t:slim X2 with G5 integration; and Tandem Device Updater, a PC and Mac-compatible tool that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:lock cartridge and infusion set products; and various pump accessories. Its products in development include automated insulin delivery systems; t:slim X2 with Basal IQ; t:slim X2 with control IQ; t:sport insulin delivery system; and connected (mobile) health mobile application. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California. Receive TNDM News and Ratings via Email Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNDM Previous Symbol CUSIPN/A Webwww.tandemdiabetes.com Phone858-366-6900Debt Debt-to-Equity RatioN/A Current Ratio2.78 Quick Ratio2.36Price-To-Earnings Trailing P/E Ratio-4.00 Forward P/E Ratio-39.31 P/E GrowthN/A Sales & Book Value Annual Sales$107.60 million Price / Sales27.46 Cash FlowN/A Price / Cash FlowN/A Book Value($2.88) per share Price / Book-17.88Profitability EPS (Most Recent Fiscal Year)($12.87) Net Income$-73,030,000.00 Net Margins-93.07% Return on Equity-204.32% Return on Assets-43.75%Miscellaneous Employees574 Outstanding Shares57,369,000Market Cap$2.95 billion OptionableOptionable Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions What is Tandem Diabetes Care's stock symbol? Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM." When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work? Tandem Diabetes Care's stock reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split. How were Tandem Diabetes Care's earnings last quarter? Tandem Diabetes Care Inc (NASDAQ:TNDM) posted its quarterly earnings data on Thursday, November, 1st. The medical device company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.28. The medical device company had revenue of $46.30 million for the quarter, compared to analysts' expectations of $42.71 million. Tandem Diabetes Care had a negative net margin of 93.07% and a negative return on equity of 204.32%. The firm's revenue for the quarter was up 71.5% compared to the same quarter last year. During the same quarter last year, the business earned ($3.09) earnings per share. View Tandem Diabetes Care's Earnings History. When is Tandem Diabetes Care's next earnings date? Tandem Diabetes Care is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Tandem Diabetes Care. How can I listen to Tandem Diabetes Care's earnings call? Tandem Diabetes Care will be holding an earnings conference call on Tuesday, February 26th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8554274396. What price target have analysts set for TNDM? 12 brokers have issued 1-year target prices for Tandem Diabetes Care's shares. Their forecasts range from $5.50 to $60.00. On average, they anticipate Tandem Diabetes Care's share price to reach $45.1250 in the next twelve months. This suggests that the stock has a possible downside of 12.4%. View Analyst Price Targets for Tandem Diabetes Care. What is the consensus analysts' recommendation for Tandem Diabetes Care? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tandem Diabetes Care. Has Tandem Diabetes Care been receiving favorable news coverage? News coverage about TNDM stock has been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tandem Diabetes Care earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned news stories about the medical device company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near future. Who are some of Tandem Diabetes Care's key competitors? Some companies that are related to Tandem Diabetes Care include Hill-Rom (HRC), Penumbra (PEN), ICU Medical (ICUI), Insulet (PODD), Novocure (NVCR), Globus Medical (GMED), Haemonetics (HAE), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR) and Atrion (ATRI). Who are Tandem Diabetes Care's key executives? Tandem Diabetes Care's management team includes the folowing people: Mr. Kim D. Blickenstaff, Pres, CEO & Director (Age 67)Mr. John F. Sheridan, Exec. VP & COO (Age 64)Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 51)Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 46)Ms. Susan M. Morrison, Exec. VP & Chief Admin. Officer (Age 40) Who are Tandem Diabetes Care's major shareholders? Tandem Diabetes Care's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.32%), Lord Abbett & CO. LLC (3.16%), Frontier Capital Management Co. LLC (2.29%), Ardevora Asset Management LLP (1.92%), Eagle Asset Management Inc. (1.83%) and Orbimed Advisors LLC (1.65%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, John F Sheridan, Kim D Blickenstaff and Richard P Valencia. View Institutional Ownership Trends for Tandem Diabetes Care. Which institutional investors are selling Tandem Diabetes Care stock? TNDM stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Frontier Capital Management Co. LLC, Barclays PLC, Millennium Management LLC, Two Sigma Advisers LP, Castleark Management LLC, Weiss Multi Strategy Advisers LLC and Squarepoint Ops LLC. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, David B Berger, John F Sheridan and Kim D Blickenstaff. View Insider Buying and Selling for Tandem Diabetes Care. Which institutional investors are buying Tandem Diabetes Care stock? TNDM stock was purchased by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Lord Abbett & CO. LLC, BlackRock Inc., Eagle Asset Management Inc., Ardevora Asset Management LLP, Orbimed Advisors LLC, Sectoral Asset Management Inc and Emerald Advisers LLC. Company insiders that have bought Tandem Diabetes Care stock in the last two years include Christopher J Twomey, Dick Allen, Kim D Blickenstaff and Richard P Valencia. View Insider Buying and Selling for Tandem Diabetes Care. How do I buy shares of Tandem Diabetes Care? Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Tandem Diabetes Care's stock price today? One share of TNDM stock can currently be purchased for approximately $51.50. How big of a company is Tandem Diabetes Care? Tandem Diabetes Care has a market capitalization of $2.95 billion and generates $107.60 million in revenue each year. The medical device company earns $-73,030,000.00 in net income (profit) each year or ($12.87) on an earnings per share basis. Tandem Diabetes Care employs 574 workers across the globe. What is Tandem Diabetes Care's official website? The official website for Tandem Diabetes Care is http://www.tandemdiabetes.com. How can I contact Tandem Diabetes Care? Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected] MarketBeat Community Rating for Tandem Diabetes Care (NASDAQ TNDM)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 392 (Vote Outperform)Underperform Votes: 391 (Vote Underperform)Total Votes: 783MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote "Outperform" if you believe TNDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNDM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: What is the NASDAQ?